Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10670607 | 0.88 | ALDH1A1 (0.67) | ALDH1A1KMT2ACA12CA1CA2 | |
| SCHEMBL10717963 | 0.88 | ALDH1A1 (0.67) | ALDH1A1KMT2ACA12CA1CA2 | |
| SCHEMBL751826 | 0.87 | HSD11B1 (0.67) | ALDH1A1LMNAKMT2ACA12CA1 | |
| SCHEMBL29354280 | 0.83 | LMNA (0.76) | ALDH1A1LMNAKMT2ACA12CA1 | |
| SCHEMBL3999414 | 0.83 | CA12 (0.68) | ALDH1A1LMNAKMT2ACA12CA1 | |
| SCHEMBL29352141 | 0.83 | LMNA (1.00) | ALDH1A1LMNAKMT2AMEN1PKM | |
| SCHEMBL18410747 | 0.83 | LMNA (0.89) | ALDH1A1LMNAKMT2AMEN1PKM | |
| SCHEMBL7073993 | 0.82 | ALDH1A1 (0.60) | ALDH1A1LMNAKMT2ACA12CA1 | |
| SCHEMBL7076666 | 0.81 | LMNA (0.72) | ALDH1A1LMNAKMT2AMEN1NPC1 | |
| SCHEMBL752323 | 0.81 | LMNA (0.72) | ALDH1A1LMNAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| WO-2016034742-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | ALDH1A1 655/4885LMNA 2505/4885KMT2A 531/4885 |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | GPR119, GLP1R, INSR | ALDH1A1 655/4885LMNA 2505/4885KMT2A 531/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 58/4885LMNA 4087/4885KMT2A 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.